COVID-19

• 217 Urinary liver-type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone-induced acute kidney injury. Nephrology (Carlton). 2023
  doi: 10.1111/nep.14254. PubMed
• 209 Urinary liver-type fatty acid binding protein is increased in the early stages of the disease with a risk of acute kidney injury induced by histone. Nephrology (Carlton).2023
  DOI: 10.1111/nep.14162 PubMed
• 208 Urinary L-Type Fatty Acid-Binding Protein Predicts Oxygen Demand of COVID-19 in Initially Mild Cases. Care Explor. 2023
  doi: 10.1097/CCE.0000000000000873. PubMed
• 204 Evaluation of Urine L-FABP Point of Care Kit in the Philippines as Predictive Marker of Clinical Severity of COVID-19 (EPOCH COVID study). Philipp J Intern Med. 2022 PJIM
• 192 Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries. Int J Infect Dis. 2022
  doi: 10.1016/j.ijid.2022.02.024. PubMed
• 191 Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J Clin Apher. 2021
  doi: 10.1002/jca.21861. PubMed
• 187 Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. J Thromb Thrombolysis. 2022
  doi: 10.1007/s11239-022-02631-7. PubMed
• 172 First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. Open Forum Infect Dis. 2021
  doi: 10.1093/ofid/ofab274. PubMed
• 171 COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. Clin Exp Nephrol. 2021
  doi: 10.1007/s10157-021-02101-z. PubMed
• 155 Evaluation of Coronavirus Disease 2019 Severity Using Urine Biomarkers. Crit Care Explor. 2020
  doi: 10.1097/CCE.0000000000000170. PubMed

Category

Acute Kidney Injury (AKI)　Chronic Kidney Disease (CKD)　Toxicology
Pharmacology　Exercise　COVID-19